Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery (EPO-CABG)

Seoul National University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Kidney Failure, Acute

Treatments: Drug: Erythropoietin-Beta; Drug: Normal Saline

Study type: Interventional

Funder types: Other

Identifiers

NCT00654992

SNUBH B-0608/036-004

Details and patient eligibility

About

The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.

Full description

Acute kidney injury (AKI) occurs in 7% to 40% of patients undergoing cardiac surgery, depending on the definition of AKI used. Even small increments in serum creatinine have been shown to be associated with increased mortality after cardiac surgery. However, there are no proven interventions to prevent AKI after cardiac surgery. Erythropoietin (EPO) has been shown to have tissue-protective effects in various experimental models. In this prospective placebo-controlled randomized trial, we evaluated the effectiveness of EPO in the prevention of AKI after coronary artery bypass grafting (CABG).

Enrollment: 71 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients scheduled for elective CABG over age 18

Exclusion criteria

• Under age 18
• Emergent CABG
• Prior exposure to nephrotoxic drug
• Dialysis patients
• Uncontrolled hypertension

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

71 participants in 2 patient groups, including a placebo group

EPO group

Active Comparator group

Treatment:

Drug: Erythropoietin-Beta

Placebo group

Placebo Comparator group

Treatment:

Drug: Normal Saline